
Jason C J Choo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6452008/publications.pdf

Version: 2024-02-01



IASON CICHOO

#	Article	IF	CITATIONS
1	Is COVID-19 vaccination unmasking glomerulonephritis?. Kidney International, 2021, 100, 469-471.	2.6	72
2	Patient-Related Barriers to Timely Dialysis Access Preparation: A Qualitative Study of the Perspectives of Patients, Family Members, and Health Care Providers. Kidney Medicine, 2020, 2, 29-41.	1.0	25
3	Long-Term Risk of Progressive Chronic Kidney Disease in Patients with Severe Acute Kidney Injury Requiring Dialysis after Coronary Artery Bypass Surgery. CardioRenal Medicine, 2015, 5, 157-163.	0.7	17
4	Desmopressin for the prevention of bleeding in percutaneous kidney biopsy: efficacy and hyponatremia. International Urology and Nephrology, 2019, 51, 995-1004.	0.6	12
5	Short-Course Systemic and Topical Non-Steroidal Anti-Inflammatory Drugs: Impact on Adverse Renal Events in Older Adults with Co-Morbid Disease. Drugs and Aging, 2021, 38, 147-156.	1.3	12
6	Serum uric acid and AKI: is it time?. CKJ: Clinical Kidney Journal, 2016, 9, 48-50.	1.4	11
7	30-year follow-up study of IgA nephritis in a Southeast Asian population: an evaluation of the Oxford histological classification. Clinical Nephrology, 2016, 86, 270-278.	0.4	11
8	Changes in metabolic parameters and adverse kidney and cardiovascular events during glomerulonephritis and renal vasculitis treatment in patients with and without diabetes mellitus. Kidney Research and Clinical Practice, 2021, 40, 250-262.	0.9	10
9	Analysis of T Cell Subsets in Adult Primary/Idiopathic Minimal Change Disease: A Pilot Study. International Journal of Nephrology, 2017, 2017, 1-13.	0.7	9
10	Comparison of Topical Chlorhexidine and Mupirocin for the Prevention of Exit-Site Infection in Incident Peritoneal Dialysis Patients. Peritoneal Dialysis International, 2017, 37, 266-272.	1.1	7
11	Risk-stratified approach to anti-viral prophylaxis against cytomegalovirus disease in glomerulonephritis and renal vasculitis treated with potent immunosuppressants. Infectious Diseases, 2019, 51, 745-752.	1.4	7
12	Healthcare professionals' perceptions of the role of a multidisciplinary approach in improving the care of patients with advanced chronic kidney disease. International Urology and Nephrology, 2020, 52, 2357-2365.	0.6	7
13	Synergistic impact of pre-diabetes and immunosuppressants on the risk of diabetes mellitus during treatment of glomerulonephritis and renal vasculitis. Kidney Research and Clinical Practice, 2020, 39, 172-179.	0.9	7
14	Statin-centric versus low-density lipoprotein-centric approach for atherosclerotic cardiovascular disease prevention: a Singapore perspective. Singapore Medical Journal, 2016, 57, 360-367.	0.3	6
15	Validation of the kidney failure risk equation in predicting the risk of progression to kidney failure in a multi-ethnic Singapore chronic kidney disease cohort. Singapore Medical Journal, 2022, 63, 313-318.	0.3	6
16	Treatmentâ€related decisional conflict in preâ€dialysis chronic kidney disease patients in Singapore: Prevalence and determinants. British Journal of Health Psychology, 2022, 27, 844-860.	1.9	6
17	Longâ€ŧerm renal outcomes in multiâ€ethnic Southeast Asians with lupus nephritis: a retrospective cohort study. Internal Medicine Journal, 2018, 48, 1117-1123.	0.5	5
18	Clinical course of Immunoglobulin A nephropathy with crescents in a multiâ€ethnic Southeast Asian cohort. Nephrology, 2020, 25, 708-713.	0.7	5

JASON C J CHOO

#	Article	IF	CITATIONS
19	The Singapore General Hospital Peritoneal Dialysis Programme from 2000–2008. Proceedings of Singapore Healthcare, 2012, 21, 132-139.	0.2	4
20	Psychosocial Factors, Intentions to Pursue Arteriovenous Dialysis Access, and Access Outcomes: A Cohort Study. American Journal of Kidney Diseases, 2021, 77, 931-940.	2.1	4
21	COVID $\hat{a} \in 19$ vaccine acceptance among patients with glomerulonephritis. Nephrology, 2022, , .	0.7	4
22	Regional evidence and international recommendations to guide lipid management in Asian patients with type 2 diabetes with special reference to renal dysfunction. Journal of Diabetes, 2018, 10, 200-212.	0.8	3
23	Newâ€onset diabetes mellitus among patients with glomerular diseases. Internal Medicine Journal, 2019, 49, 101-108.	0.5	3
24	Non-Steroidal Anti-Inflammatory Drugs and Risk of Acute Kidney Injury and Hyperkalemia in Older Adults: A Retrospective Cohort Study and External Validation of a Clinical Risk Model. Drugs and Aging, 2022, 39, 75-82.	1.3	3
25	Asymptomatic proteinuria, renal cysts and dorsal pancreas agenesis. CKJ: Clinical Kidney Journal, 2014, 7, 411-412.	1.4	2
26	Copeptin, myeloperoxidase and pro-adrenomedullin for acute coronary syndrome in patients with chronic kidney disease. Proceedings of Singapore Healthcare, 2019, 28, 173-183.	0.2	2
27	Chlorhexidine-impregnated sponge dressing for prevention of catheter exit-site infection in peritoneal dialysis patients: a pilot study. International Urology and Nephrology, 2021, 53, 803-812.	0.6	2
28	Non-steroidal anti-inflammatory drugs and risk of acute adverse renal outcomes in diabetes and diabetes diabetic kidney disease. International Journal of Risk and Safety in Medicine, 2021, , 1-10.	0.3	2
29	Native kidney biopsies in older adults: disease spectrum, long-term kidney and patient survival and safety. International Urology and Nephrology, 2022, , 1.	0.6	2
30	Do Foxp3+ Regulatory T Cells (Treg Cells) Play a Role in the Immunopathogenesis of Primary/Idiopathic Minimal Change Disease?. ISRN Pathology, 2014, 2014, 1-8.	0.4	1
31	Age-adjusted global glomerulosclerosis in addition to Oxford histological classification of IgA nephropathy. Kidney International, 2018, 93, 1250.	2.6	1
32	Letter to the Editor: Time for cost-effectiveness studies for preventive strategies applied according to risk of cytomegalovirus-related morbidity and mortality in ANCA-associated vasculitis. Clinical Rheumatology, 2018, 37, 2011-2012.	1.0	1
33	Hyponatremia may be an underâ€recognized complication after desmopressin to reduce uremic bleeding in kidney biopsy. Nephrology, 2019, 24, 674-674.	0.7	1
34	Estimation of risk for major bleeding in native kidney biopsies in patients with multiple risk factors. International Urology and Nephrology, 2022, 54, 343-348.	0.6	1
35	Cardiovascular risk assessment in lupus nephritis and ANCA-associated vasculitis in real-world nephrology practice. CKJ: Clinical Kidney Journal, 0, , .	1.4	1
36	Antineutrophil cytoplasmic antibodyâ€associated necrotizing glomerulonephritis: Not always pauciâ€immune. Nephrology, 2013, 18, 579-579.	0.7	0

JASON C J CHOO

#	Article	IF	CITATIONS
37	SP435RENAL OUTCOMES OF TYPE 2 DIABETIC PATIENTS WITH NON DIABETIC KIDNEY DISEASES. Nephrology Dialysis Transplantation, 2018, 33, i495-i495.	0.4	0
38	Abnormal Chest Radiograph in Rapidly Progressive Glomerulonephritis—Not the Usual Pulmonary-Renal Syndrome. American Journal of Medicine, 2019, 132, 1163-1165.	0.6	0
39	The Case An unusual cause of renal impairment and hematuria in aortic dissection. Kidney International, 2019, 96, 255-256.	2.6	0
40	Infection mitigation a necessity in lupus patients. Clinical Rheumatology, 2019, 38, 261-262.	1.0	0
41	Pseudohyperkalemia with concurrent tumor lysis syndrome in extreme leukocytosis: Diagnostic and management pitfalls. Journal of Onco-Nephrology, 2020, 4, 117-120.	0.3	0
42	Effectiveness and acceptability of a multidisciplinary approach in improving the care of patients with advanced chronic kidney disease: a pilot study. International Urology and Nephrology, 2022, 54, 917-926.	0.6	0
43	Hypothyroidism-induced kidney dysfunction: an under-recognized phenomenon in patients on immune checkpoint inhibitors. CKJ: Clinical Kidney Journal, 0, , .	1.4	0
44	Individualizing immunosuppressive therapy decision in Immunoglobulin A nephropathy and application in a Southeast Asian cohort. CKJ: Clinical Kidney Journal, 0, , .	1.4	0
45	Immune-complex membranoproliferative glomerulonephritis in liver cirrhosis secondary to Caroli's disease: a multi-hit process?. International Urology and Nephrology, 2022, , 1.	0.6	0